544 related articles for article (PubMed ID: 19416085)
1. In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions.
Kindla J; Fromm MF; König J
Expert Opin Drug Metab Toxicol; 2009 May; 5(5):489-500. PubMed ID: 19416085
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Knop J; Misaka S; Singer K; Hoier E; Müller F; Glaeser H; König J; Fromm MF
PLoS One; 2015; 10(10):e0139370. PubMed ID: 26426900
[TBL] [Abstract][Full Text] [Related]
3. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
4. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.
Smith NF; Figg WD; Sparreboom A
Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):429-45. PubMed ID: 16863454
[TBL] [Abstract][Full Text] [Related]
5. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.
Bachmakov I; Glaeser H; Fromm MF; König J
Diabetes; 2008 Jun; 57(6):1463-9. PubMed ID: 18314419
[TBL] [Abstract][Full Text] [Related]
6. Organic anion transporting polypeptides 1B1 and 1B3 play an important role in uremic toxin handling and drug-uremic toxin interactions in the liver.
Sato T; Yamaguchi H; Kogawa T; Abe T; Mano N
J Pharm Pharm Sci; 2014; 17(4):475-84. PubMed ID: 25579430
[TBL] [Abstract][Full Text] [Related]
7. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
Rizk ML; Houle R; Chan GH; Hafey M; Rhee EG; Chu X
Antimicrob Agents Chemother; 2014; 58(3):1294-301. PubMed ID: 24295974
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate.
Zhang Y; Panfen E; Fancher M; Sinz M; Marathe P; Shen H
Mol Pharm; 2019 Jun; 16(6):2342-2353. PubMed ID: 31039308
[TBL] [Abstract][Full Text] [Related]
9. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
[TBL] [Abstract][Full Text] [Related]
10. Prediction of organic anion-transporting polypeptide 1B1- and 1B3-mediated hepatic uptake of statins based on transporter protein expression and activity data.
Kunze A; Huwyler J; Camenisch G; Poller B
Drug Metab Dispos; 2014 Sep; 42(9):1514-21. PubMed ID: 24989890
[TBL] [Abstract][Full Text] [Related]
11. Screening of antibiotics that interact with organic anion-transporting polypeptides 1B1 and 1B3 using fluorescent probes.
Yamaguchi H; Takeuchi T; Okada M; Kobayashi M; Unno M; Abe T; Goto J; Hishinuma T; Shimada M; Mano N
Biol Pharm Bull; 2011; 34(3):389-95. PubMed ID: 21372390
[TBL] [Abstract][Full Text] [Related]
12. Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport.
Kindla J; Müller F; Mieth M; Fromm MF; König J
Drug Metab Dispos; 2011 Jun; 39(6):1047-53. PubMed ID: 21389119
[TBL] [Abstract][Full Text] [Related]
13. OATP1B3 Expression and Function is Modulated by Coexpression with OCT1, OATP1B1, and NTCP.
Zhang Y; Ruggiero M; Hagenbuch B
Drug Metab Dispos; 2020 Aug; 48(8):622-630. PubMed ID: 32482756
[TBL] [Abstract][Full Text] [Related]
14. Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance.
Lee HH; Leake BF; Kim RB; Ho RH
Mol Pharmacol; 2017 Jan; 91(1):14-24. PubMed ID: 27777271
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.
Shitara Y; Maeda K; Ikejiri K; Yoshida K; Horie T; Sugiyama Y
Biopharm Drug Dispos; 2013 Jan; 34(1):45-78. PubMed ID: 23115084
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of hepatic uptake transporters by flavonoids.
Mandery K; Balk B; Bujok K; Schmidt I; Fromm MF; Glaeser H
Eur J Pharm Sci; 2012 May; 46(1-2):79-85. PubMed ID: 22394605
[TBL] [Abstract][Full Text] [Related]
17. In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters.
Durmus S; Naik J; Buil L; Wagenaar E; van Tellingen O; Schinkel AH
Int J Cancer; 2014 Oct; 135(7):1700-10. PubMed ID: 24554572
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence-based assays for the assessment of drug interaction with the human transporters OATP1B1 and OATP1B3.
Bednarczyk D
Anal Biochem; 2010 Oct; 405(1):50-8. PubMed ID: 20540932
[TBL] [Abstract][Full Text] [Related]
19. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Karlgren M; Vildhede A; Norinder U; Wisniewski JR; Kimoto E; Lai Y; Haglund U; Artursson P
J Med Chem; 2012 May; 55(10):4740-63. PubMed ID: 22541068
[TBL] [Abstract][Full Text] [Related]
20. Interaction of digitalis-like compounds with liver uptake transporters NTCP, OATP1B1, and OATP1B3.
Gozalpour E; Greupink R; Wortelboer HM; Bilos A; Schreurs M; Russel FG; Koenderink JB
Mol Pharm; 2014 Jun; 11(6):1844-55. PubMed ID: 24754247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
